Burosumab in infants with X-linked hypophosphatemic rickets: a case series

Abstract Background X-linked hypophosphatemic rickets (XLH) is a rare inherited metabolic bone disorder caused by excess fibroblast growth factor 23 (FGF23), leading to hypophosphatemia and rickets. Burosumab, a human monoclonal antibody targeting FGF23, was approved for the treatment of XLH in Apri...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ravit Regev, Avivit Brener, Nitzan Dror, Raphael Krespi, Rebeca Rapalino, Efrat Chorna, Ophir Borger, Adar Lopez, Yael Lebenthal, Leonid Zeitlin
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2026-01-01
Edice:	Orphanet Journal of Rare Diseases
Témata:	X-linked hypophosphatemic rickets XLH Burosumab Infants Linear growth Rickets score
On-line přístup:	https://doi.org/10.1186/s13023-025-04177-2
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!